case_images: PMC10616240_01
case_images: Computed tomography (CT) imaging of lung lesions at critical time point during the treatment course.
case_images: fimmu-14-1270828-g001.jpg
case_images: PMC10616240_01_fimmu-14-1270828-g001.jpg
case_images: f1
case_images: The maximum diameters of these two nodules were 13mm and 14mm for the right and the left lung, respectively ( Figure 1 ). The patient achieved partial response (PR) on March 14th ( Figure 1 ), with significant shrinkage of both lesions: the left lung lesion was measuring 8mm and the right lung lesion 5mm. The dosage was then increased to 240mg (2 doses) every 3 weeks, and a subsequent efficacy evaluation on September 19th, after two cycles of treatment, indicated a response of left lung lesion to 5mm ( Figure 1 ). The disease remained in continuous response at our last follow-up, August 17th, 2023 ( Figure 1 ).
case_images: The treatment history of a patient with advanced clear-cell renal carcinoma treated with PD-1 rechallenge.
case_images: fimmu-14-1270828-g002.jpg
case_images: PMC10616240_01_fimmu-14-1270828-g002.jpg
case_images: f2
case_images: Entire treatment history of the patient was showed in  Figure 2 .